Neumora Therapeutics (NMRA) Return on Invested Capital (2025 - 2026)
Neumora Therapeutics' quarterly Return on Invested Capital came in at 0.02% in Q1 2026, down 1.0% year-on-year from 0.02% in Q1 2025, and up 4.73% quarter-over-quarter from 0.02% in Q4 2025.
Neumora Therapeutics has reported Return on Invested Capital for 2 years, with the latest figure at 0.02% in Q1 2026.
- For the quarter ending Q1 2026, Return on Invested Capital fell 1.0% year-over-year to 0.02%; the trailing twelve-month figure through Mar 2026 stood at 0.02% (down 1.0% YoY), and the FY2025 full-year result was 0.01%, changed 0.0% from the prior year.
- Return on Invested Capital for Q1 2026 stood at 0.02%, up from 0.02% in the prior quarter.
- The five-year high for Return on Invested Capital was 0.01% in Q1 2025, with the low at 0.02% in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -0.01% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -0.01% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.01% |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - | -0.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.02% |
| Dec 31, 2025 | -0.02% |
| Sep 30, 2025 | -0.02% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | -0.01% |